Are Bitovil/Bikonprenol tablets classified as blocking drugs? Detailed explanation of mechanism of action and indications

Biktarvy is a fixed-dose combination antiviral drug used to treat human immunodeficiency virus type 1 (HIV-1) infection. Its main ingredients include bictegravir sodium (bictegravir), emtricitabine (emtricitabine) and tenofovir alafenamide (TAF), which jointly exert a synergistic antiviral effect. Although it is not usually called a "blocking drug", from a mechanism point of view, it does "block" virus replication at a key node in the virus life cycle, so it makes sense for patients to commonly call it a "blocking drug."

Bictegravir sodium is an integrase strand transfer inhibitor (INSTI). It inhibits HIV integrase and prevents the integration of viral DNA into the host cell genome, thereby interrupting the key steps of viral replication. Emtricitabine and tenofovir alafenamide are respectively nucleoside reverse transcriptase inhibitors (NRTIs), which can be embedded into the DNA chain synthesized by the virus, causing chain termination, thereby further inhibiting virus amplification. This three-drug-in-one fixed-dose combination not only improves the efficacy, but also simplifies the treatment plan, greatly improving patients' medication compliance.

Bitovil is suitable for untreated HIV-1 infected patients and can also be used for conversion treatment in patients with controlled viral replication (HIV RNA <50 copies/mL) and no history of drug resistance. Clinical trials have proven that it has strong efficacy, high safety, and broad inhibitory effect on multiple HIV subtypes. It has been included as one of the first-line recommended treatment options by the US CDC and WHO. As an antiviral drug that is taken orally once a day, Bituvi achieves a good balance between the antiviral effect and the patient's quality of life, and represents the current development direction of anti-HIV treatment.

Reference materials:https://www.biktarvy.com/